Paradigm Capital Management Inc. NY Purchases New Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Paradigm Capital Management Inc. NY bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 404,001 shares of the medical instruments supplier's stock, valued at approximately $3,701,000. Paradigm Capital Management Inc. NY owned about 1.00% of AngioDynamics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Systematic Financial Management LP raised its holdings in shares of AngioDynamics by 4.6% in the fourth quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier's stock valued at $23,093,000 after purchasing an additional 110,719 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in AngioDynamics by 10.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier's stock valued at $13,636,000 after buying an additional 135,007 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of AngioDynamics by 55.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock worth $12,963,000 after buying an additional 503,713 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of AngioDynamics by 37.4% during the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier's stock worth $11,875,000 after buying an additional 353,070 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in shares of AngioDynamics by 13.5% in the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock worth $10,254,000 after buying an additional 133,312 shares during the last quarter. Institutional investors own 89.43% of the company's stock.

AngioDynamics Price Performance

Shares of NASDAQ ANGO traded up $0.04 during mid-day trading on Friday, reaching $9.45. 390,130 shares of the company's stock were exchanged, compared to its average volume of 553,720. The firm has a 50-day moving average price of $9.47 and a two-hundred day moving average price of $9.49. The firm has a market capitalization of $383.74 million, a price-to-earnings ratio of -1.68 and a beta of 0.58. AngioDynamics, Inc. has a 52 week low of $5.47 and a 52 week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. The business's quarterly revenue was down 4.3% on a year-over-year basis. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.